PMID- 36845849
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230325
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 14
DP  - 2023
TI  - Role of abatacept in the prevention of graft-versus-host disease: current 
      perspectives.
PG  - 20406207231152644
LID - 10.1177/20406207231152644 [doi]
LID - 20406207231152644
AB  - Administration of abatacept following transplantation has been reported to 
      inhibit graft rejection and graft-versus-host-disease (GvHD) in mouse models 
      associated with allogeneic hematopoietic stem cell transplant (HSCT). This 
      strategy has recently been adopted in clinical practice for GvHD prevention in 
      human allogeneic HSCT and offers a unique approach to optimizing GvHD prophylaxis 
      following alternative donor HSCTs. When combined with calcineurin inhibitors and 
      methotrexate, abatacept had shown to be safe and effective in preventing moderate 
      to severe acute GvHD in myeloablative HSCT using human leukocyte antigen (HLA) 
      unrelated donors. Equivalent results are being reported in recent studies using 
      alternative donors, in reduced-intensity conditioning HSCT and nonmalignant 
      disorders. These observations have led to hypothesizing that even in the setting 
      of increasing donor HLA disparity, abatacept when given with traditional GvHD 
      prophylaxis does not worsen general outcomes. In addition, in limited studies, 
      abatacept have being protective against the development of chronic GvHD through 
      extended dosing and in the treatment of steroid-refractory chronic GvHD. This 
      review summarized all the limited reports of this novels approach in the HSCT 
      setting.
CI  - (c) The Author(s), 2023.
FAU - Ngwube, Alexander
AU  - Ngwube A
AUID- ORCID: 0000-0003-4780-5642
AD  - Center for Cancer and Blood Disorders, Phoenix Children's Hospital, 1919 East 
      Thomas Road, Phoenix, AZ 85016-7710, USA.
FAU - Rangarajan, Hemalatha
AU  - Rangarajan H
AUID- ORCID: 0000-0003-3371-2920
AD  - Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, 
      Nationwide Children's Hospital, Columbus, OH, USA.
FAU - Shah, Niketa
AU  - Shah N
AD  - Section of Pediatric Hematology Oncology and Bone Marrow transplant, Yale School 
      of Medicine, New Haven, CT, USA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230209
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC9943961
OTO - NOTNLM
OT  - abatacept
OT  - allogeneic hematopoietic stem cell transplantation
OT  - graft-versus-host disease
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/02/28 06:00
MHDA- 2023/02/28 06:01
PMCR- 2023/02/09
CRDT- 2023/02/27 05:24
PHST- 2022/04/06 00:00 [received]
PHST- 2022/11/28 00:00 [accepted]
PHST- 2023/02/27 05:24 [entrez]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/02/28 06:01 [medline]
PHST- 2023/02/09 00:00 [pmc-release]
AID - 10.1177_20406207231152644 [pii]
AID - 10.1177/20406207231152644 [doi]
PST - epublish
SO  - Ther Adv Hematol. 2023 Feb 9;14:20406207231152644. doi: 
      10.1177/20406207231152644. eCollection 2023.